Chest
-
Lung Cancer ISESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 02:15 PM - 03:45 PMPURPOSE: To report local control and overall survival following CyberKnife treatment for central NSCLC conventional radiation failures. ⋯ Sean Collins: Consultant fee, speaker bureau, advisory committee, etc.: Consultant Accuray Inc. Brian Collins: Consultant fee, speaker bureau, advisory committee, etc.: Speaker Bureau Accuray Inc. The following authors have nothing to disclose: Ryan Malik, Shaan Kataria, Catherine Jamis, Leonard Chen, Simeng Suy, Cristina Reichner, Eric AndersonNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Current COPD treatment guidelines recommend long-acting β2-agonist/inhaled corticosteroids (LABA/ICS) for severe COPD patients with a history of exacerbations. The 26-week ILLUMINATE study in moderate-to-severe COPD patients showed superiority of QVA149 versus the LABA/ICS salmeterol/fluticasone combination (SFC) in lung function. A novel study design to evaluate the effect of QVA149 versus SFC on COPD exacerbations in more severe patients with a history of exacerbations is presented. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Nicola Gallagher: Employee: Novartis employee Donald Banerji: Employee: Novartis employee The following authors have nothing to disclose: Jørgen VestboClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA is in the late stage phase 3 trials prior to approval.
-
Pleural Disease/Pleural Effusion PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The aim of this work was to assess the concordance between chest ultrasound (US) and chest CT findings prior to medical thoracoscopy (MT), the impact of the findings on the conduct and outcome of MT and whether US alone or in combination with chest X-ray (CXR) can be sufficient for imaging assessment before the procedure. ⋯ The following authors have nothing to disclose: Magdy Khalil, Haytham Samy, Hanan Hosny, Emad Edward, Ehab Thabet, Wael Emara, Ahmad Soliman, Hanaa FayezNo Product/Research Disclosure Information.
-
Cancer Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMPURPOSE: An 80 year old female nonsmoker presented with a 20 lb weight loss and dysphagia. She had a normal colonoscopy and esophagogastroduodenoscopy. She had no risk factors for tuberculosis and no travel to Midwestern or South eastern United States. On PE she had a BMI of 24 with no palpable adenopathy and a normal exam ⋯ The following authors have nothing to disclose: Tuhina Raman, Mary IacoccaNo Product/Research Disclosure Information.
-
Pleural Disease/Pneumothorax PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Pneumothorax continues to be a major cause of morbidity and mortality among the respiratory patients but there is paucity of data regarding aetiology, clinical profile, management and outcome of Spontaneous Pneumothorax (SP) from this part of the world. Therefore, this study was carried out to determine the aetiology, clinical presentation, management and outcomes of Spontaneous pneumothorax in a tertiary care Hospital from eastern India. ⋯ The following authors have nothing to disclose: Aparup Dhua, Sourin Bhuniya, Arunabha Datta Chaudhuri, Sumit Raytapadar, Tapan Das BairagyaNo Product/Research Disclosure Information.